Big Pharma's newest member, AbbVie (NYSE:ABBV), hit the ground running when it split off from Abbott Labs (NYSE:ABT) early in 2013. The stock's taken the markets by storm in its inaugural year, gaining more than 27% year-to-date in a standout performance for investors. But AbbVie's much more than just a surging stock in 2013 with growth potential: It also delivers a top dividend in a health-care sector that's long been a great play by stability-minded income investors.
However, AbbVie's not without red flags. The company's heavily reliant on mega-blockbuster immunology drug Humira, which provided $9 billion in sales last year and fuels more than half of the company's revenue. Such a focus on one product isn't the hallmark of the market's best dividend stocks, but is AbbVie worth your investment?
In the following video, Motley Fool contributor Dan Carroll discusses what income investors can take away from this surging stock -- and how AbbVie is much more than just Humira and change.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.